ArticleOncology and therapy2025
Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.
Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04500535 (A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment (LIST, Lung Initiative on Sequence Therapy)
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advancing immune checkpoint inhibitor rechallenge: key insights into efficacy, safety, and personalized strategies in advanced solid tumors.Frontiers in oncology · 2026Pooled it
- Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitorsJournal of enzyme inhibition and medicinal chemistry · 2026Review
- Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.Oncology and therapy · 2026Article
- Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.Oncology and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNivolumab is approved in France as monotherapy for the treatment of advanced (locally advanced or metastatic) non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study is evaluating the real-world effectiveness, safety and immunotherapy-rechallenge outcomes with nivolumab in previously treated French patients with aNSCLC.
methodsThis longitudinal, prospective, observational study enrolled patients with aNSCLC who received ≥ 1 prior line of treatment that included chemotherapy. Three patient cohorts, based on prior treatment, were assessed: immunotherapy-naïve (cohort 1; prior chemotherapy, no prior immunotherapy), and immunotherapy-experienced, including patients who discontinued prior immunotherapy for reasons other than immunotherapy-related toxicity (cohort 2) and those who discontinued because of immunotherapy-related toxicity (cohort 3). The primary endpoint was time to treatment discontinuation (TTD). Results after at least 12 months of follow-up are reported.
resultsAt data cut-off (September 2024), 522 patients were enrolled. In cohort 1 (N = 280), cohort 2 (N = 197) and cohort 3 (N = 45), the 12-month TTD rate was 17.7% (95% CI 13.4, 22.5), 14.4% (95% CI 9.8, 19.8) and 16.7% (95% CI 7.3, 29.2), respectively. The main reason for nivolumab discontinuation was disease progression. Younger patients, those with better performance status (PS), longer prior immunotherapy duration and prolonged benefit with prior immunotherapy had numerically higher discontinuation-free rates. Median PFS was 3.2, 2.7 and 3.9 months (95% CI 2.7-4.1, 2.2-3.4, 2.2-7.4), and median overall survival (OS) was 12.3, 9.5 and 10.4 months (95% CI 8.6-13.7, 7.2-11.3, 7.6-20.1) in cohorts 1, 2 and 3, respectively. Any-grade treatment-related adverse events were reported in 36.1%, 25.0% and 37.0% of patients in the respective cohorts.
conclusionsThe 1-year results of LIST show consistent effectiveness and safety of nivolumab in immunotherapy-experienced patients, especially in specific subgroups. Nivolumab safety in patients with prior immunotherapy-related toxicity appeared to be consistent with its expected safety profile.
trial registrationClinicalTrials.gov identifier NCT04500535.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.